CRISPR Therapeutics stock gets a November gene editing data date ?????????? no

Published on 10/05/2026 at 12:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CRISPR Therapeutics stock posted USD 10.2 million in Q2 2026 revenue, versus USD 0.9 million a year earlier. The loss narrowed to USD 0.94 per share from USD 2.40.

CRSP, CH0334081137, Illustration mit AI erstellt.

CRISPR Therapeutics stock (ISIN CH0334081137) was last at USD 55.43 on Nasdaq on October 2, 2026, as the company set a November date for new clinical data. CRISPR Therapeutics said on October 2, 2026, that it will present Phase 1 data for zugo-cel in refractory systemic sclerosis at ACR Convergence.

November data date raises pipeline stakes

The poster presentation is scheduled for November 8, 2026, at 10:30 a.m. ET and will examine safety and efficacy for an investigational, gene-edited allogeneic CAR T therapy targeting CD19. The program is being evaluated across rheumatologic, hematologic and neurologic autoimmune diseases, giving the event significance beyond a single indication.

The clinical update adds a defined checkpoint to a pipeline that spans hemoglobinopathies, cardiovascular disease, autoimmune disease, oncology, regenerative medicine and rare diseases. CRISPR Therapeutics also identifies CASGEVY, developed with Vertex Pharmaceuticals, as its approved CRISPR-based therapy for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia.

Q2 revenue beat points to collaboration income

Zacks reported that second-quarter 2026 revenue reached USD 10.2 million, versus USD 0.9 million in the year-ago quarter and a USD 7 million consensus estimate. The quarter's loss narrowed to USD 0.94 per share from USD 2.40, beating the USD 1.10 consensus loss.

The revenue mix matters: Zacks said USD 10 million came from collaboration revenue, with the remainder from grants. Research and development expense was USD 67.2 million in Q2 2026, down 3.9 percent from the year-ago quarter, while acquired in-process research and development expense fell to USD 2.5 million from USD 96.3 million.

Analysts see room above the last price

Ticker Nerd counted 22 analysts covering CRISPR Therapeutics as of October 3, 2026, with 13 Buy ratings and 9 Hold ratings. The median 12-month target was USD 80, while targets ranged from USD 44 to USD 291.

At USD 55.43 on October 2, the median target stood USD 24.57 above the last price, a 44.3 percent difference. That gap places the November clinical presentation alongside the quarterly revenue trajectory as the next measurable test for the valuation.

CRSP stays below its yearly high

CRSP's October 2 Nasdaq range was USD 54.08 to USD 57.58, with volume of 1,131,218 shares. The USD 55.43 last price stood below the 52-week high of USD 78.48 and above the 52-week low of USD 44.12; market capitalization was USD 5.3 billion as of October 2, 2026.